The delay is made to provide the FDA with more time to review and respond to information and materials provided by Gen-Probe in connection with the Panel meeting and the premarket approval application for the Progensa PCA3 Assay.

The advisory panel said the review of the Progensa PCA3 Assay could take place in the first quarter of 2012.